Clinical trial · Observational
Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F
NCT02470364CI-TRIAL-00018265MGQOL-15-FcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to translate and culturally adapt the MGQOL-15 (health-related quality of life scale for myasthenia gravis) for use with French-speaking patients in France and to evaluate its psychometric properties to ensure reliability and validity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Perceived quality of life measured via the MGQOL-15-F (French version of the MGQOL-15), a myasthenia-specific quality of life auto-questionnaire
- timeFrame
- 3 days
Secondary outcomes (4)
- measure
- Global quality of life evaluated via the WHOQOL-BREF scale
- timeFrame
- 1 day
- measure
- Clinical evaluation : Myasthenic Muscle Score
- timeFrame
- 1 day
- measure
- Disease severity assessed via the Myasthenic Muscle Score
- timeFrame
- 1 day
- measure
- Impact of symptoms on daily activities and daily life using the MG-ADL score
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Auto-immune myasthenia gravis * Age ≥ 18 years old * Clinical Classification (MGFA) I-IV * French speaking Exclusion Criteria: * cognitive or visual impairment which would limit the capacity to fill out the MGQOL-15-F
References
Publications (0)
Data not yet available
No reference posted for this study.